Raising the bar for chronic GVHD trials

Abstract

In this issue of Blood, Martin et al propose a new primary endpoint for clinical studies on chronic graft-versus-host disease (GVHD). Their results from a prospective multicenter observational study are helpful for designing future clinical trials in the treatment of chronic GVHD because the endpoint was shown to be associated with clinical benefit for the patient.1